Stimufend (Pegfilgrastim)

What Is Stimufend and What Is It Used For?

Stimufend belongs to a class of medicines called cytokines, more specifically the granulocyte colony-stimulating factor (G-CSF) family. G-CSF is a naturally occurring protein produced primarily by endothelial cells, macrophages, and fibroblasts in response to infection or stress. It regulates the production, maturation, and release of neutrophils — the white blood cells that form the body's first line of defense against bacterial and fungal pathogens. The active substance in Stimufend, pegfilgrastim, is a recombinant form of human G-CSF that has been covalently linked to a single 20 kDa polyethylene glycol (PEG) molecule. This pegylation is the feature that distinguishes pegfilgrastim from its parent molecule, filgrastim.

The addition of the PEG chain substantially increases the hydrodynamic size of the protein, which markedly reduces renal clearance. As a result, pegfilgrastim is eliminated almost exclusively through neutrophil-mediated clearance: the G-CSF receptors expressed on mature neutrophils internalize and degrade the drug. This self-regulating mechanism means that as neutrophil counts rise back to normal, pegfilgrastim is automatically removed from the circulation, providing a pharmacologically elegant feedback loop. The practical consequence is that a single subcutaneous injection of Stimufend provides sufficient G-CSF stimulation to cover an entire chemotherapy cycle, typically 14–21 days, whereas short-acting filgrastim requires daily injections for 10–14 days.

Stimufend is a biosimilar medicine, which means it has been developed to be highly similar to an already authorized biological reference medicine — in this case, Amgen's Neulasta (the originator pegfilgrastim). Biosimilars are not generics: because biological medicines are large, complex proteins produced in living cells, exact replication is not possible. Instead, regulatory agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) approve biosimilars only after comprehensive head-to-head comparability studies have demonstrated equivalent pharmaceutical quality, pharmacokinetics, pharmacodynamics, efficacy, safety, and immunogenicity to the reference product. Stimufend received EMA marketing authorization in 2023 following this rigorous evaluation.

Approved Indication

Stimufend has a single, tightly defined indication: reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy, with the exception of chronic myeloid leukemia (CML) and myelodysplastic syndromes (MDS). This exclusion exists because G-CSF may theoretically stimulate malignant myeloid clones in these specific diseases.

Febrile neutropenia is defined as an absolute neutrophil count (ANC) below 0.5 × 10⁹/L accompanied by a single oral temperature of ≥38.3 °C or a sustained temperature of ≥38.0 °C for more than one hour. It is a medical emergency: without prompt broad-spectrum antibiotic therapy, mortality can exceed 10%, and it is one of the most common causes of unplanned hospitalization in patients undergoing chemotherapy. By accelerating neutrophil recovery, pegfilgrastim reduces both the depth and the duration of the post-chemotherapy neutrophil nadir, thereby lowering the incidence of febrile neutropenia, infection-related hospitalizations, and chemotherapy dose delays or reductions.

When Is Pegfilgrastim Prophylaxis Recommended?

International oncology guidelines (ESMO, NCCN, ASCO, EORTC) recommend primary G-CSF prophylaxis — meaning use from the first chemotherapy cycle — when the expected risk of febrile neutropenia is ≥20%. This threshold is based on a risk-benefit calculation that accounts for the cost, side effects, and inconvenience of prophylaxis versus the severity of neutropenic complications. Regimens known to exceed this threshold include dose-dense AC-T (doxorubicin plus cyclophosphamide followed by paclitaxel) in breast cancer, BEACOPP in Hodgkin lymphoma, and R-CHOP-14 in aggressive non-Hodgkin lymphoma in elderly patients.

When febrile neutropenia risk is between 10% and 20%, prophylaxis is considered based on patient-specific risk factors such as advanced age (especially >65 years), poor performance status, previous chemotherapy or radiotherapy, pre-existing neutropenia, tumor bone marrow infiltration, recent surgery, open wounds, active infection, or significant comorbidities. For risks below 10%, routine prophylaxis is generally not recommended.

Pegfilgrastim is also used for secondary prophylaxis — in subsequent cycles after a patient has experienced febrile neutropenia or a dose-limiting neutropenic event during a previous cycle — to preserve chemotherapy dose intensity. Maintaining the planned dose intensity is important because multiple randomized trials and meta-analyses have demonstrated that chemotherapy dose reductions and delays are associated with inferior cancer-specific survival in several tumor types, including early-stage breast cancer and aggressive lymphomas.

Mechanism of Action

At the molecular level, pegfilgrastim binds to the G-CSF receptor (CSF3R / CD114) expressed on neutrophil precursor cells in the bone marrow. Receptor dimerization triggers activation of the intracellular JAK2/STAT3, PI3K/Akt, and Ras/MAPK signaling pathways. These pathways jointly promote survival, proliferation, differentiation, and functional activation of the granulocyte lineage. The effects are observable within 24 hours of injection and include a rapid mobilization of mature neutrophils from the bone marrow reserve, followed by sustained production of new neutrophils over the following two weeks.

Pegfilgrastim also augments the functional activity of mature neutrophils, including enhanced chemotaxis toward sites of infection, phagocytosis of opsonized pathogens, and the respiratory burst that generates microbicidal reactive oxygen species. In addition, pegfilgrastim mobilizes hematopoietic stem and progenitor cells from the bone marrow into the peripheral blood, though this effect is not a labeled indication for Stimufend.

What Should You Know Before Taking Stimufend?

Contraindications

Stimufend must not be used if you are hypersensitive (allergic) to pegfilgrastim, to filgrastim, or to any of the excipients listed in the contents section, including sorbitol (E420), acetate buffer, polysorbate 20, and sodium. If you have previously experienced a hypersensitivity reaction to any filgrastim- or pegfilgrastim-containing product — even one from a different manufacturer — you should not receive Stimufend, as cross-reactivity between G-CSF biosimilars is possible.

The needle shield on the pre-filled syringe may contain dry natural rubber (a derivative of latex), which in patients with severe latex allergy can trigger contact reactions or, very rarely, anaphylaxis. Patients with confirmed latex allergy should inform their healthcare provider before injection.

Warnings and Precautions

Before starting treatment with Stimufend, tell your doctor about your full medical history, including any of the following:

• Sickle cell disease or sickle cell trait: G-CSF products have been associated with sickle cell crises — sometimes severe and occasionally fatal — in patients with these conditions. Stimufend should be used with caution, with appropriate clinical monitoring, adequate hydration, and a clear plan for early intervention if symptoms emerge.
• Pre-existing splenomegaly (enlarged spleen): Additional enlargement and, rarely, rupture have been reported.
• Osteoporosis or low bone density: Although the evidence is limited, long-term G-CSF use may affect bone metabolism. Patients on prolonged treatment should have bone health monitored.
• Autoimmune disease: Cutaneous vasculitis and Sweet's syndrome have been reported, most frequently in patients with a history of inflammatory disease.
• Recent thoracic radiotherapy or pulmonary disease: Interstitial lung disease and acute respiratory distress syndrome (ARDS) are recognized risks.

Patients should be aware that pegfilgrastim can induce a transient increase in white blood cell counts to 100 × 10⁹/L or higher, typically between day 2 and day 8 after injection. This physiological leukocytosis is expected and does not require specific intervention, although a complete blood count at baseline and after chemotherapy is advisable.

In patients with non-myeloid malignancies, pegfilgrastim is generally well tolerated; however, in certain tumor types with a significant myeloid component, theoretical concerns about stimulation of malignant clones have led to the exclusion of CML and MDS from the labeled indication. If a new bone marrow disorder is suspected during pegfilgrastim treatment, therapy should be discontinued and specialist hematology evaluation obtained.

Sequential use with bleomycin-containing regimens requires special caution. Several case series and registry data suggest that G-CSF administration concurrent with or shortly after bleomycin may increase the risk of pulmonary toxicity, including fatal pneumonitis. When bleomycin-containing regimens such as ABVD or BEACOPP are used, the timing of pegfilgrastim should be discussed carefully with the treating hematologist and pulmonary function should be monitored closely.

Pregnancy and Breastfeeding

There are limited data on the use of pegfilgrastim in pregnant women. Animal studies have shown reproductive toxicity at supratherapeutic doses, including increased post-implantation loss and reduced mean fetal body weight. Stimufend is therefore not recommended during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment and for a period afterward as determined by the oncology team.

It is not known whether pegfilgrastim or its metabolites are excreted in human breast milk. Because many biological medicines are excreted in human milk, and because of the potential for adverse reactions in the nursing infant (although oral absorption of intact proteins is generally very limited), a decision must be made either to discontinue breastfeeding or to discontinue Stimufend, taking into account the importance of therapy to the mother.

Fertility

There are no clinical data on the effect of pegfilgrastim on human fertility. Animal studies in rats have not shown adverse effects on fertility at clinically relevant doses, but results cannot be directly extrapolated to humans. Patients with concerns about future fertility should discuss fertility preservation options with their oncology team before starting chemotherapy.

Driving and Operating Machinery

Stimufend has no or negligible influence on the ability to drive and use machines. However, patients who experience dizziness, weakness, or significant bone pain should refrain from driving until the symptoms have resolved.

Important Information About Excipients

How Does Stimufend Interact with Other Drugs?

As a biological medicine, pegfilgrastim does not interact with other drugs through the cytochrome P450 system, transporters, or protein binding in the way that small-molecule medicines do. Nonetheless, a number of clinically relevant interactions have been identified, primarily based on the pharmacodynamic effects of G-CSF on the bone marrow.

The most important principle is separation from cytotoxic chemotherapy. Pegfilgrastim stimulates rapid proliferation of myeloid progenitor cells. If a cytotoxic agent is present in the circulation at the same time, these rapidly dividing cells may be more sensitive to chemotherapy-induced damage, potentially worsening rather than ameliorating myelosuppression. For this reason, pegfilgrastim should not be administered in the 14-day period before the next chemotherapy cycle or within 24 hours after the completion of the current cycle.

Major Interactions

Minor and Theoretical Interactions

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including non-prescription products, herbal remedies, or dietary supplements. Although pegfilgrastim has few direct drug-drug interactions, the complexity of oncology regimens means that careful medication reconciliation is always warranted.

What Is the Correct Dosage of Stimufend?

The dosing of Stimufend is deliberately simple. Because pegfilgrastim is a long-acting G-CSF, a single fixed dose is administered once per chemotherapy cycle, regardless of body weight in adults weighing 45 kg or more. This single-dose convenience is one of the main practical advantages of pegfilgrastim over daily filgrastim, which requires 10–14 injections per cycle.

Adults

For adults aged 18 years and older, the recommended dose is 6 mg of pegfilgrastim administered as a single subcutaneous injection per chemotherapy cycle. The injection is typically given approximately 24 hours after the last dose of cytotoxic chemotherapy within a cycle. Earlier administration (<24 hours) has not been adequately studied and may theoretically reduce efficacy by exposing rapidly proliferating myeloid cells to residual chemotherapy. Later administration (>72 hours) is also suboptimal because it narrows the window of myelopoietic support before the nadir.

Injection sites include the front of the thigh, the abdomen (avoiding a 5 cm circle around the navel), or the upper outer area of the buttocks. If a caregiver administers the injection, the outer upper arm may also be used. Rotate injection sites between cycles to reduce the risk of local reactions.

Children and Adolescents

Stimufend is not specifically indicated for use in children and adolescents under 18 years of age. Published clinical experience with pegfilgrastim in pediatric oncology exists, primarily for acute lymphoblastic leukemia, lymphomas, and solid tumors, but reflects off-label use. In pediatric practice, a weight-based dose of 0.1 mg/kg (maximum 6 mg) has been used in centers where pegfilgrastim is preferred over daily filgrastim. Decisions in this population should be made by specialist pediatric hematology-oncology teams who can weigh the evidence and individual circumstances.

Elderly Patients

No specific dose adjustment is required for patients aged 65 years or older. However, elderly patients are more likely to have coexisting cardiovascular, renal, or pulmonary disease, and the consequences of severe adverse events such as splenic rupture or capillary leak syndrome can be more serious. Closer clinical monitoring is appropriate, and thresholds for investigation of new symptoms should be lower.

Renal and Hepatic Impairment

Pegfilgrastim is eliminated primarily through receptor-mediated clearance by mature neutrophils, not through renal filtration or hepatic metabolism. Pharmacokinetic studies have shown no clinically significant differences in exposure between patients with normal organ function and those with end-stage renal disease, including patients on dialysis. As a result, no dose adjustment is required for any degree of renal or hepatic impairment.

Missed Dose

Because Stimufend is given only once per chemotherapy cycle, the concept of a "missed dose" is different from that of daily medications. If the scheduled injection is missed or delayed by more than 72 hours after chemotherapy, contact the oncology team promptly. The team will decide whether to give a delayed injection, accepting some reduction in protective efficacy, or to rely on careful monitoring and provide alternative supportive care during the nadir. Do not administer two doses in the same cycle to compensate.

Overdose

There is limited clinical experience with pegfilgrastim overdose. In healthy volunteer studies, single doses up to 300 mcg/kg have been administered without dose-limiting toxicity. Expected findings following accidental overdose would include a greater than normal increase in white blood cell count, more pronounced bone pain, and potentially a higher risk of splenomegaly and thrombocytopenia. Management is supportive and includes clinical monitoring, complete blood counts, and symptomatic treatment of bone pain. There is no specific antidote; the receptor-mediated clearance mechanism provides intrinsic self-limitation.

Self-Injection Instructions

Many patients are able to administer Stimufend themselves at home after receiving appropriate training from a nurse or pharmacist. Self-injection is convenient and avoids the need for an extra clinic visit on the day after chemotherapy. The following steps summarize the procedure:

1. Warm the syringe to room temperature for approximately 30 minutes before use. Do not use heat sources.
2. Wash hands thoroughly and prepare a clean, well-lit workspace.
3. Inspect the syringe — the solution should be clear and colorless. Discard if cloudy, discolored, or containing particles.
4. Select an injection site: abdomen (>5 cm from navel), front of thigh, or upper outer area of buttocks. Rotate between cycles.
5. Clean the skin with an alcohol swab and allow to air-dry.
6. Remove the needle cap; do not replace it. Do not touch the needle.
7. Pinch the skin and insert the needle at a 45–90° angle in a single motion.
8. Inject slowly and steadily until the syringe is empty.
9. Withdraw the needle; apply gentle pressure with sterile gauze. Do not rub.
10. Dispose of the syringe in an approved sharps container immediately. Each syringe is for single use only.

What Are the Side Effects of Stimufend?

Like all medicines, Stimufend can cause side effects, although not everyone experiences them. The adverse event profile of pegfilgrastim is dominated by bone pain, which is a direct pharmacological consequence of increased bone marrow activity and is shared by all G-CSF products. Most reactions are mild to moderate and self-limiting. Serious reactions are rare but require prompt recognition and management.

Importantly, many of the side effects reported in clinical trials — particularly nausea, fatigue, mucositis, thrombocytopenia, anemia, and alopecia — are also features of the underlying cancer or of the concurrent cytotoxic chemotherapy. Attribution to pegfilgrastim specifically should be made with this overlap in mind.

Side Effects by Frequency

Understanding Bone Pain

Bone pain is the signature adverse effect of pegfilgrastim and occurs because the drug dramatically increases cellular activity within the bone marrow. The pain is usually felt in the lower back, pelvis, long bones of the legs, ribs, and sternum — anywhere with active hematopoietic marrow. It typically begins 1–3 days after injection and lasts 2–7 days. Intensity ranges from mild ache to severe, debilitating pain in a minority of patients.

Management strategies include scheduled (rather than as-needed) use of paracetamol (acetaminophen) 500–1000 mg every 6 hours or, if not contraindicated by the chemotherapy regimen or platelet count, non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen. Several randomized trials have also suggested that loratadine 10 mg daily for 5 days starting the day of pegfilgrastim injection reduces bone pain severity, possibly by antagonizing histamine release from mast cells in the marrow. Opioids are reserved for severe cases where first-line measures have failed.

Splenic Events

Splenic enlargement is a recognized consequence of G-CSF therapy in a minority of patients, most commonly in those with severe chronic neutropenia or in healthy stem cell donors. In rare cases, the enlarged spleen may rupture, producing severe left-upper-quadrant pain, hypotension, and tachycardia. Splenic rupture can occur with no warning symptoms beforehand and has been reported after a single dose of pegfilgrastim in previously healthy patients. Any sudden left-sided abdominal pain, particularly pain referred to the left shoulder tip (Kehr's sign), should be investigated urgently with ultrasound or CT.

Pulmonary Adverse Events

Pulmonary infiltrates, interstitial lung disease, and acute respiratory distress syndrome (ARDS) have all been reported during G-CSF therapy. The mechanism is thought to involve margination of activated neutrophils in the pulmonary capillary bed, with subsequent release of oxidative and proteolytic mediators. Patients who develop new respiratory symptoms — particularly cough, dyspnea, or hypoxia — during or shortly after a chemotherapy cycle should have a chest imaging study and early consideration of G-CSF-associated lung injury in the differential diagnosis.

How Should You Store Stimufend?

Correct storage is particularly important for biological medicines like pegfilgrastim because the active substance is a large, folded protein that can lose its biological activity if exposed to unfavorable conditions. Temperature excursions, light exposure, and mechanical stress can all cause misfolding, aggregation, or chemical modification of the molecule, potentially compromising efficacy and immunogenicity.

• Refrigerate: Store in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Ensure the refrigerator is not placed against an external wall where it may be colder than expected and do not store syringes in the door where temperatures fluctuate.
• Protect from light: Keep the pre-filled syringe inside the outer carton until use. Light exposure, particularly ultraviolet, can cause oxidative degradation of the protein.
• Do not freeze: Freezing disrupts the three-dimensional structure of pegfilgrastim and can also cause the formation of micro-aggregates that increase the risk of immunogenicity. Accidental single exposure to freezing temperatures for less than 24 hours does not affect stability according to most biosimilar SmPCs, but repeated freeze-thaw cycles or prolonged freezing requires the product to be discarded.
• Room temperature storage: The syringe may be removed from the refrigerator and stored at room temperature (not above 30 °C / 86 °F) for a single period of up to 72 hours. After that period, the product must be discarded and must not be returned to the refrigerator. Always check the specific package insert for your batch, as some biosimilars specify 25 °C or slightly different timeframes.
• Do not shake: Mechanical agitation can cause foaming and protein denaturation. Transport gently.
• Before injection: Allow the syringe to reach room temperature for approximately 30 minutes for a more comfortable injection. Do not warm artificially.
• Visual inspection: Before every use, check that the solution is clear and colorless or slightly yellow. Do not use if the solution appears cloudy, strongly discolored, or contains visible particles. Check that the expiration date on the label has not passed.
• Keep out of children's reach: Store in a safe location inaccessible to children or pets.

Disposal

Used syringes must be disposed of immediately in an approved sharps container — a puncture-proof plastic container that can be obtained from pharmacies or healthcare providers. Do not put the syringe in household waste, do not attempt to recap the needle, and do not flush down the toilet. Many countries and hospitals offer free sharps disposal programs; ask your pharmacist for the nearest collection point.

Unused or expired medicines should not be disposed of via wastewater or household waste either. Return them to a pharmacy for safe destruction, in accordance with national and local environmental regulations. These measures help protect the environment and prevent accidental exposure.

Travel Considerations

Patients who need to travel during their chemotherapy schedule should plan pegfilgrastim storage carefully. Use an insulated cool-bag with ice packs (not direct contact with the syringe) to maintain 2–8 °C during transit. For air travel, request a medical cold storage letter from the oncology service and carry the syringe in hand luggage — never check it in, as cargo hold temperatures can fall well below freezing. Most airlines will accommodate reasonable requests for small refrigerated storage during flights with advance notice.

What Does Stimufend Contain?

Understanding the full composition of Stimufend is important for patients with known allergies or intolerances to specific excipients, and for healthcare professionals reviewing compatibility with intravenous lines, diluents, or concomitant medications. The following sections describe the active substance and all other components.

Active Substance

The active substance is pegfilgrastim, produced by recombinant DNA technology in Escherichia coli and then covalently conjugated to a single 20 kDa monomethoxypolyethylene glycol (mPEG) molecule at the N-terminal methionine residue of filgrastim. The resulting conjugate has a molecular weight of approximately 39 kDa and retains the receptor-binding and biological activity of filgrastim while exhibiting dramatically extended pharmacokinetics.

Each pre-filled syringe of Stimufend contains:

• 6 mg of pegfilgrastim in 0.6 ml of solution, corresponding to a concentration of 10 mg/ml (based on protein only).

Other Ingredients (Excipients)

• Sodium acetate — buffer, formed by titration of glacial acetic acid with sodium hydroxide
• Sorbitol (E420) — tonicity agent and stabilizer (30 mg per syringe)
• Polysorbate 20 — surfactant that prevents protein aggregation at the air-liquid interface
• Water for injections — solvent

The formulation contains no preservatives, so each syringe is intended for single use only. Any unused medicine must be discarded. The acetate buffer maintains a pH around 4.0, which is the optimal range for the stability of the pegfilgrastim molecule. This acidic pH explains the transient stinging sensation sometimes felt during the injection.

Appearance and Packaging

Stimufend is a clear, colorless solution for subcutaneous injection, supplied in a 1 ml Type I glass pre-filled syringe equipped with a fixed 27-gauge, 12.7 mm stainless steel needle. The needle shield contains a derivative of natural rubber latex; patients with confirmed latex allergy should use an alternative presentation or a different biosimilar. Depending on the market, the syringe may be supplied with or without a passive safety device that covers the needle after injection.

Stimufend is packaged in cartons containing 1 pre-filled syringe. Not all pack sizes may be marketed in every country. The marketing authorization holder is Fresenius Kabi Deutschland GmbH, with manufacturing performed at Fresenius Kabi facilities within the European Economic Area.

Biosimilar Status

Stimufend is approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) as a biosimilar of Amgen's Neulasta (pegfilgrastim). Comprehensive comparability data — including physicochemical characterization, in vitro potency assays, pharmacokinetic/pharmacodynamic studies in healthy volunteers, and clinical efficacy/safety trials in patients with breast cancer receiving chemotherapy — demonstrated that Stimufend is highly similar to the reference product. Biosimilar approval does not mean generic; rather, it means the medicine has undergone the full rigorous pathway required for biological products.

References

This article is based on evidence from internationally recognized medical sources. All information has been reviewed for accuracy against current clinical guidelines and peer-reviewed research.

1. European Medicines Agency (EMA). Stimufend: EPAR – Product Information. Available at: EMA – Stimufend.
2. European Medicines Agency (EMA). Neulasta: EPAR – Scientific Discussion and Product Information (reference product). Available at ema.europa.eu.
3. U.S. Food and Drug Administration (FDA). Stimufend (pegfilgrastim-fpgk) Prescribing Information. Fresenius Kabi USA, LLC.
4. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(28):3199-3212. doi:10.1200/JCO.2015.62.3488
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. Version 1.2025.
6. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118.
7. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8-32. doi:10.1016/j.ejca.2010.10.013
8. Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24(10):2475-2484. doi:10.1093/annonc/mdt226
9. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29-35.
10. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178-1184.
11. World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: World Health Organization.
12. British National Formulary (BNF). Pegfilgrastim. National Institute for Health and Care Excellence (NICE). Available at bnf.nice.org.uk.
13. European Medicines Agency (EMA). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005 Rev1. 2014.
14. Kirshner JJ, McDonald MC 3rd, Kruter F, et al. NOLAN: A randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Support Care Cancer. 2018;26(4):1323-1334.
15. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10(11):1235-1244.

Medical Editorial Team

This article was written and reviewed by the iMedic Medical Editorial Team, which includes board-certified physicians specializing in oncology, hematology, and clinical pharmacology. Our team follows international editorial standards and the GRADE evidence framework to ensure all medical information is accurate, current, and evidence-based.

Last reviewed: February 1, 2026 | Next scheduled review: August 1, 2026